ClinicalTrials.Veeva

Menu

Evaluation of the Analgesic Benefit of Adding the Blocks of the Intermediate and Medial Femoral Cutaneous Nerves in Addition to the Femoral Triangle Block for Postoperative Analgesia After a Knee Replacement Surgery

C

Centre hospitalier de l'Université de Montréal (CHUM)

Status

Completed

Conditions

Anesthesia, Local
Post-operative Pain

Treatments

Procedure: Femoral Triangle Block (FTB)
Procedure: Para-Sartorial Compartments (PACS) Block
Procedure: Infiltration between popliteal artery and capsule of the knee (IPACK) block

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Total knee replacement surgery can be associated with a significant postoperative pain burden and an inability to mobilize adequately, which can lead to the failure of the ambulatory course.

Indeed, early mobilization is beneficial in this context in order to prevent complications related to immobility.

The optimization of postoperative analgesia is therefore a key issue for the success of this intervention in an outpatient setting or during a short-term hospitalization since an adequate pain relief facilitate the earlier mobilization of the operated joint. Modern postoperative analgesia protocols recommend a multimodal approach, including the use of acetaminophen, anti-inflammatories, opioids and others as well as the use of nerve blocks.

Some nerve blocks used for total knee replacement surgery, such as the femoral nerve block, do not preserve the motor skills of the operated limb, which may alter the clinical trajectory due to delayed mobilization due to weakening of the quadriceps, one of the extensor muscles of the knee. Currently, one of the blocks used to spare the motor functions is the block of the femoral triangle.

Unfortunately, this block of the femoral triangle does not fully cover the skin component of the surgical incision used for a total knee arthroplasty. A solution to obtain a better quality of pain relief at the level of the cutaneous incision would be to add a block of the para-sartorial compartment, which makes it possible to cover the nerve territories not covered by the femoral triangle block.

The hypothesis of this study is that the addition of the para-sartorial compartments (PACS) block, which aims to block the intermediate cutaneous femoral nerve, will improve the postoperative analgesia after total knee replacement surgery, compared to the classical isolated approach of the femoral triangle block (FTB).

Full description

Despite many advances, the postoperative analgesia offered by the present techniques remains imperfect, the femoral triangle block does not make it possible to completely cover the cutaneous component of the classic midline incision used for a total knee arthroplasty. This incision would fall more under the anterior cutaneous femoral nerves, more specifically the intermediate and medial cutaneous femoral nerves. A recently described approach offers the prospect of better covering this skin incision, by specifically blocking these nerves using the same needle path as for the femoral triangle block. Although the feasibility of this approach has been studied in healthy volunteers and in a few clinical cases, no randomized controlled study has been conducted to determine whether the addition of cutaneous femoral nerve blocks offers an analgesic benefit in the population undergoing total knee replacement surgery. This is therefore necessary in order to assess whether this approach improves the clinical trajectory of patients receiving a total knee arthroplasty.

Enrollment

122 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18 years and over, requiring a primary total knee arthroplasty
  • 'American Society of Anesthesiologists' classification 1 to 3

Exclusion criteria

  • Refusal or unable to consent
  • Contraindications to a peripheral nerve block;
  • Inability to communicate with the healthcare team or the research team;
  • Inability to understand follow-up instructions or questionnaires;
  • Chronic pain requiring the intake of the equivalent of more than 60 mg of morphine daily;
  • Pregnancy;
  • Patients weighing less than 50 kg (to limit the risk of intoxication with local anesthetics).

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

122 participants in 2 patient groups

Para-Sartorial Compartment (PACS) Block + Femoral Triangle Block (FTB) + IPACK block
Experimental group
Description:
In addition to the injection performed in the femoral triangle, two injections of 5 mL of 0.5% ropivacaine + epi 1:400 000 will be performed below the sartorius muscle (subsartorial compartment) and above the sartorius muscle (suprasartorial compartment). For all patients, an infiltration between popliteal artery and capsule of the knee block (IPACK) will be performed concomitantly, in order to block the sensory branches of the innervation posterior to the knee with 15 ml of ropivacaine 0.3% + epi 1:400 000.
Treatment:
Procedure: Infiltration between popliteal artery and capsule of the knee (IPACK) block
Procedure: Femoral Triangle Block (FTB)
Procedure: Para-Sartorial Compartments (PACS) Block
Femoral Triangle Block (FTB) + IPACK block
Active Comparator group
Description:
This block is currently the most used in practice and is considered a standard of care. It consists of a single injection of 15 ml of 0.5% ropivacaine + epi 1:400 000 under the sartorius muscle, lateral to the femoral artery, at the level of the apex of the femoral triangle For all patients, an infiltration between popliteal artery and capsule of the knee block (IPACK) will be performed concomitantly, in order to block the sensory branches of the innervation posterior to the knee with 15 ml of ropivacaine 0.3% + epi 1:400 000.
Treatment:
Procedure: Infiltration between popliteal artery and capsule of the knee (IPACK) block
Procedure: Femoral Triangle Block (FTB)

Trial contacts and locations

1

Loading...

Central trial contact

Maxim Roy, MD, FRCPC; Julie Desroches, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems